# Chikungunya PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/chikungunya

> The FDA approved chikungunya, sponsored by Valneva SE (VALN), on December 3, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | chikungunya |
| Codes | VLA1553 |
| Sponsor | Valneva SE (VALN) https://sec-api.dev/companies/valn/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 2022: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001628280-25-014522): "We announced completion of recruitment for this trial in June 2021 and positive topline and final data from this trial in December 2021 and May 2022, respectively." https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001628280-25-014522): "Additionally, we initiated a Phase 2 pediatric trial in children 1 to 11 years of age, VLA1553-221, in January 2024 to support a Phase 3 pivotal pediatric study and potentially extend the label in this age group following initial regulatory approvals in adults and possibly in adolescents." https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm

### December 3, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-03, last confirmed 2024-12-03.
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006682): "4 Valneva Announces U.S. FDA Approval of World's" https://www.sec.gov/Archives/edgar/data/1836564/000117184324006682/exh_991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/chikungunya.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chikungunya PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/chikungunya

```bibtex
@misc{secapidev_pdufa_chikungunya_20261116,
  title        = {Chikungunya PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/chikungunya}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_chikungunya_20261116","title":"Chikungunya PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/chikungunya","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
